47 results
6-K
EX-99.1
QNTM
Quantum BioPharma Ltd
27 Sep 24
Quantum Biopharma Provides Corporate Update
8:09pm
of approximately C$130 million and could be utilized in the future to offset tax payable obligations against future profits. Quantum BioPharma retains 100 … loss to offset future tax payable obligations against future profits; the Company’s intention to retain 100% of the rights to develop products
6-K
EX-99.1
QNTM
Quantum BioPharma Ltd
16 Sep 24
Quantum BioPharma Closes Private Placement Offering
7:27am
in the future to offset tax payable obligations against future profits. Quantum BioPharma retains 100% of the rights to develop similar product
6-K
EX-99.1
QNTM
Quantum BioPharma Ltd
6 Sep 24
Quantum Biopharma Receives Nasdaq Notification of Regaining Compliance with Nasdaq’s Minimum Bid Price Requirement and Completes Debt Settlements
9:22pm
retains a large tax loss carry forward of approximately C$130 million and could be utilized in the future to offset tax payable obligations against … on the research and development of Lucid-MS to prevent and reverse myelin degradation; the Company’s intention to utilize its large tax loss to offset future tax
6-K
EX-99.1
QNTM
Quantum BioPharma Ltd
26 Aug 24
Quantum Biopharma Announces Intention to Complete Debt Settlements and Provides Corporate Update
6:18am
be utilized in the future to offset tax payable obligations against future profits. Quantum BioPharma retains 100% of the rights to develop similar … tax loss to offset future tax payable obligations against future profits; the Company’s intention to retain 100% of the rights to develop products
6-K/A
EX-99.2
QNTM
Quantum BioPharma Ltd
19 Aug 24
Condensed consolidated interim financial statements
5:18pm
research and development activities offset by an increase in prepaid insurance.
Finance receivables, current and non-current, decreased by $1,619,150
6-K
EX-99.1
isoi09oco
15 Aug 24
Current report (foreign)
7:07am
6-K
EX-99.2
k8yc2serlnknz9kaeg
14 Aug 24
Condensed consolidated interim financial statements
6:13am
6-K
EX-99.1
z7rlour
12 Aug 24
FSD Pharma Announces Share Consolidation and Name Change
6:03am
6-K
EX-99.1
j7c3g0q v6r4zg0og
29 Jul 24
FSD Pharma Inc. Announces Results of Annual General and Special Meeting of Shareholders
9:04pm
6-K
EX-99.2
b2a 8wdy3r
8 Jul 24
Amended and Restated Material Change Report
3:20pm
6-K
EX-99.1
xzpm9
28 Jun 24
FSD Pharma provides Corporate Update
5:01pm
6-K
EX-99.1
mtb82v4
28 Jun 24
Current report (foreign)
7:49am
6-K
EX-99.1
jxobad v9snbf
27 Jun 24
Current report (foreign)
7:34am
6-K
EX-99.1
u5021kbyrny32zvgt
13 Jun 24
Current report (foreign)
7:31am
6-K
EX-99.1
twu2bml08w3 bp4b
4 Jun 24
FSD Pharma Receives Institutional Review Board Approval to Study the Safety and Efficacy of Unbuzzd™ in Acute Alcohol Intoxication
8:28am
6-K
EX-99.1
yn0r3wps7e uz3
31 May 24
Current report (foreign)
7:30am
6-K
EX-99.2
y7ji5 44hu
15 May 24
Condensed consolidated interim financial statements
6:02am
6-K
EX-99.2
d2t0o13 s30bcvbjw
15 Nov 23
Condensed consolidated interim financial statements
12:00am